Syndax Pharmaceuticals
Logotype for Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals (SNDX) investor relations material

Syndax Pharmaceuticals Stifel 2026 Healthcare Conference 2026 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Syndax Pharmaceuticals Inc
Stifel 2026 Healthcare Conference 2026 summary12 Nov, 2026

Commercial performance and outlook

  • Revuforj new patient starts rose 20% sequentially; expected continued quarterly growth from KMT2A and NPM1 penetration, with NUP98 also a potential treatment population.

  • About 50% of patients reach transplant and 50%-60% return to maintenance; KMT2A maintenance returns are trending toward 70%-80%.

  • Maintenance is expected to contribute more visibly to revenue in 2027, including as NPM1 patients return to therapy.

  • Niktimvo has about one-third share in 3L+ GVHD; expansion beyond the current ~6,000-patient market toward 15,000-17,000 patients is a growth opportunity.

  • Niktimvo growth is expected from further share gains and longer treatment duration; margins were 30%-35% this quarter, up from 25%-30% in prior quarters.

Menin program and frontline studies

  • Management characterized J&J’s bleximenib abstract as early and cautioned that patient populations and efficacy-evaluable definitions complicate comparisons; combinations and tolerability will be important differentiators.

  • ASH presentations will include frontline Ven/Aza combination data from BEAT AML, with high CR rates and median OS expected to exceed 24 months, plus intensive-chemotherapy data showing high CR, ORR and MRD clearance.

  • Separate Phase III studies address intensive chemotherapy and Ven/Aza populations; the international study has multiple hundred active enrolling sites and is at least 30% smaller than some competitor trials.

  • Both Phase III studies have independently powered dual primary endpoints, supporting potential success on either endpoint and an accelerated approval pathway; management cited strong enrollment momentum and a competitive readout timeframe.

  • MenTain will prospectively randomize patients after transplant to assess maintenance; RAVEN tests Ven/Aza as a bridge to transplant for fit patients with KMT2A AML.

Niktimvo development

  • A 120-patient, three-arm Phase II study is expected to report in Q1 2027; its six-month response benchmark is about 40%, and it is powered to assess a 20% delta between active arms.

  • Duration of response and event-free survival, alongside response rate and tolerability, will inform whether axatilimab plus ruxolitinib can reduce steroid exposure and support uptake.

  • Further frontline development, including a possible axatilimab-ruxolitinib study, will be considered after review of the upcoming datasets and clinician input.

  • A pivotal frontline study is expected to read out in Q1 2028, comparing Niktimvo strategies with steroids and seeking to reduce steroid use.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Syndax Pharmaceuticals earnings date

Logotype for Syndax Pharmaceuticals Inc
UBS Global Biopharma Conference 202617 Nov, 2026
Syndax Pharmaceuticals
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Syndax Pharmaceuticals earnings date

Logotype for Syndax Pharmaceuticals Inc
UBS Global Biopharma Conference 202617 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Syndax Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for cancer. The company's lead programs target immune pathways and tumor microenvironments to enhance the body’s ability to fight cancer. Syndax's pipeline includes treatments for both solid tumors and hematologic cancers, aiming to address unmet medical needs by improving outcomes for cancer patients through novel combination therapies. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.